Cancer Research Institute (CRI)

CRI Postdoctoral Fellow Dr. Falcomatà at Icahn School of Medicine at Mount Sinai is leading cutting-edge research aimed at uncovering how pancreatic cancer cells evade the immune system. Discover how your support is fueling her impact in accelerating lifesaving cancer immunotherapy research: https://bit.ly/4hiBiGT #PancreaticCancer #Immunotherapy #CancerResearch

Aiming to improve the understanding of immune cell organization in ovarian cancer, a new study from researchers including CRI-Irvington Postdoctoral Fellow Dr. Ayana Ruffin of Emory University and former CRI-V Foundation CLIP Investigator Dr. Tullia Bruno of University of Pittsburgh sheds light on the development of tertiary lymphoid structures (TLS) in different tumor sites from patients with high-grade serous ovarian cancer. Explore their findings, and discover how their insights could eventually lead to new treatment approaches for ovarian cancer: https://bit.ly/4fisi2M #Immunotherapy #OvarianCancer #CancerResearch

For CRI Scientific Advisory Council Associate Director Dr. Jedd Wolchok of Weill Cornell Medicine, immunotherapy has always been a question not of “if” but “when," Princeton Alumni Weekly describes. "I saw that it wasn’t a question of whether it was real, but a matter of making the clinical successes more frequent,” he expresses. Discover: https://bit.ly/4hbHwsj #Immunotherapy #CancerResearch #CancerResearcher

Discover how researchers from Columbia University including CRI Lloyd J. Old STAR Dr. Tal Danino are "opening the door for a new class of cancer vaccines that take advantage of bacteria's natural tumor-targeting properties," with Medical Xpress: https://bit.ly/407Z42r #CancerVaccines #CancerResearch #Immunotherapy

A groundbreaking study from CRI affiliated scientists, including CRI-Thompson Family Foundation CLIP Investigator Dr. Juan R. Cubillos-Ruiz, CRI-Sandra Schnitzer Fellow Dr. Camilla Salvagno, and former Dr. Keith Landesman Memorial Fellow Dr. Chang-Suk Chae of Weill Cornell Medicine, former CRI CLIP Investigator Dr. Jose Ramon Conejo-Garcia of Duke University School of Medicine, and CRI Clinical Accelerator Investigator Dr. Dmitry Zamarin of Icahn School of Medicine at Mount Sinai, demonstrates how ovarian cancer cleverly hampers immune cells by cutting off their energy supply. Ovarian cancer manipulates the TAGLN2 protein, which helps fatty acid binding protein 5 (FABP5) transport essential fatty acids needed for T cell energy and effective anti-tumor responses. Researchers observed how ovarian tumor-induced stress reduces TAGLN2 levels, leaving T cells starved for fatty acids and less effective at fighting cancer. Restoring TAGLN2 not only revives T cell energy, but also boosts the effectiveness of CAR T cell therapy in preclinical models. Continue to explore how this discovery paves the way for innovative strategies to enhance immunotherapy for ovarian cancer patients: https://lnkd.in/eRKEs_-y #OvarianCancer #CancerResearch #Immunotherapy

Exciting findings from CRI Lloyd J. Old STAR Dr. Haydn Kissick of Emory University reveal a unique, stem-like T cell population with a surprising dual role, that can either suppress, or activate tumor-fighting T cells. In tumor-draining lymph nodes, these PD1+TCF1+ CD4 T cells switch character based on their surroundings. They remain stem-like in the presence of regulatory T cells (Tregs) to limit tumor immune responses, or transform into T helper 1 (TH1) cells to activate tumor fighting CD8+ T cells for stronger tumor control when T regs are absent. This discovery opens new doors to understanding how to harness these T cells in order to improve cancer therapies. Explore: https://lnkd.in/eF4mdR5K #CancerResearch #Immunotherapy

During our 2024 fiscal year, the Cancer Research Institute invested $22.8 million in research grants and awards, across 42 institutions in 7 countries. Discover how CRI-funded researchers are making a global impact, by exploring our latest Impact Report: https://bit.ly/4hiBiGT #CancerResearch #Immunotherapy #GiveWithConfidence

Can your diet change your immune system? Join researchers as they explore "exactly how nutrition acts on the immune system to boost health and treat disease," in a new article from Springer Nature's Nature: https://lnkd.in/eczMbt-b #CancerResearch #Microbiome #Immunology

The Cancer Research Institute’s investment in research is making a difference and expanding the impact of immunotherapy, with 29 cancers now treatable using these approaches. Over the past year, there have been 13 new FDA approvals for immunotherapy treatments, covering 10 different drugs and 11 types of cancer. Together, we are supporting groundbreaking discoveries, bringing hope to patients, and redefining the future of cancer treatment. Continue to explore our impact: https://bit.ly/4hiBiGT #CancerResearch #Immunotherapy

🏆 The Cancer Research Institute's 2024 Annual Awards Gala celebrated the leaders and innovators who are driving lifesaving cancer immunotherapy research. Discover the people powering progress who were honored at this event, hear an ImmunoAdvocate's story of survival, and dive into the next chapter for CRI and for the immunotherapy revolution, in our recap of the evening: https://bit.ly/4fbR6tg #CancerResearch #Immunotherapy #CRIGala24